Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Topigen begins Phase II trial of COPD drug
The drug, TPI 1020, is a novel, anti-inflammatory respiratory drug licensed from NicOx for respiratory indications. The trial is expected to enroll approximately 50 evaluable patients. The primary
The drug, TPI 1020, is a novel, anti-inflammatory respiratory drug licensed from NicOx for respiratory indications. The trial is expected to enroll approximately 50 evaluable patients. The primary
Skura said that the SFX suite is the most advanced sales/marketing tablet PC detailing software available. It enables pharmaceutical and life sciences companies to detail the right physician,
The decision means that this patent covering a multiple unit tablet is still valid in Austria, Belgium, Switzerland, Germany, Denmark, Spain, France, UK, Greece, Ireland, Italy, Liechtenstein, Luxembourg,
The amounts sold include 279,000 shares of preferred stock issued pursuant to the underwriters’ exercise of the overallotment option. The offerings generated net proceeds, after underwriting discounts and
The positive opinion is based on results from the ACUITY trial of 13,819 patients with acute coronary syndromes (ACS), which found that Angiox with or without a glycoprotein
<p>The acquisition bolsters PolyPeptide Laboratories' manufacturing capacity and capabilities, from small-scale custom peptides for research to large-scale peptides for therapeutic applications. Such capabilities complement the group's long-established core
<p>Under the terms of the agreement, Alios will provide Cleveland Clinic an upfront license fee, various development, regulatory and commercial milestones, and royalties on net sales. In addition,
<p>In return for the sale of its assets which consist of the PDE inhibitors, the LSAIDs and the protein therapeutics technology, Inflazyme receives $4 million in cash and
<p>Medicare beneficiaries in Oklahoma can sign up for or switch Medicare Part D prescription drug coverage during the 2008 annual open enrollment period, which begins November 15 and
<p>The license agreement allows Daiichi Sankyo to use the PER.C6 cell line in its early stage research to identify new antibodies and for the production of preclinical grade